AR019153A1 - Compuestos de beta-carbolina, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento y compuesto intermediario - Google Patents

Compuestos de beta-carbolina, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento y compuesto intermediario

Info

Publication number
AR019153A1
AR019153A1 ARP990102812A ARP990102812A AR019153A1 AR 019153 A1 AR019153 A1 AR 019153A1 AR P990102812 A ARP990102812 A AR P990102812A AR P990102812 A ARP990102812 A AR P990102812A AR 019153 A1 AR019153 A1 AR 019153A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
phenyl
thiophene
alkylamino
Prior art date
Application number
ARP990102812A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR019153A1 publication Critical patent/AR019153A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compuesto de beta-carbolina que se unen a receptores de somatostatina y bloquean canales Na que tienen la formula (I), las mezclas racémicas-diasteroméricas y los isomeros opticos del anteriormente mencionado compuesto de formula (I), las sales farmacéuticamente aceptables o prodrogas deéste o una sal aceptable farmacéuticamente de la antedicha prodroga, en donde: - - - representa un enlace opcional; X es N o N-R4, donde X es N cuyosenlaces opcionales están presentes y X es N-R cuyos enlaces opcionales no están presentes; R1 es H, -(CH2)m-C(O)-(CH2)mZ1, (CH2)mZ1, -(CH2)m-OZ1 o C0-6-alquilo-C(O)-NH-(CH2)mZ3; Z1 es una porcion opcionalmente sustituida seleccionada del grupo que consiste en alquilo C1-12, benzo [b] tiofeno, fenilo, naftilo,benzo[b] furanilo, tiofeno, esoxazolilo, indolilo, formula (II); R2 es alquilo C1-12, C0-6 alquilo -C(O)-O-Z5, C0-6-alquilo-C(O)-NH-(CH2)m-Z3 o feniloopcionalmente sustituido; Z5 es H, C1-12 alquilo o (CH2)m-arilo; Z3 es amino, C1-12 alquiloamino, N,N-di-C1-12 alquiloamino-NH-C(O)-(CH2)m-fenilo,-NH-C(O)-(CH2)m-C1-8 alquilo o una porcion opcionalmente sustituida seleccionada del grupo compuesto por imidazolilo, piridinilo y morfolinilo, piperidinilo,piperazinilo, pirazolidinilo, furanilo y tiofeno;R3 es H; R4 es H, -C(=Y)-N(X1-X2), C(=O)X2OX2; Y es O o S; X2 es -(CH2)m-Y1-X3; X3 es H o una porcionopcionalmente sustituida seleccionada del grupo compuesto por C1-12 alquilo, C3-8 cicloalquilo, C1-12 alcoxido, ariloxido, C1-12 alquilamino, N,N-di-C1-12 alquilamino, -CH-di-C1-12 alcoxido o fenilo; R5 es C1-12 alquilo, -(CH2)mY--(CH2)m-fenil(X1)n, C1-12 cicloalquilo, -(CH2)m-S-C1-12 alquilo,C1-12 alquilo-S-S- C1-12 alquilo, -(CH2)m-C1-12 alquenilo o una porcion opcionalmente sustituido seleccionada del grupo compuesto de fenilo, furanilo,tiofeno, pirrolilo y piridinilo y formula (III); Y1 es O, S, NH o un enlace; R6 es H o SO2-fenilo; R7 es H, alquilo opcionalmente sustituido con alcoxido odialquilamino; en donde una porcion opcionalmentesustituida o fenilo opcionalmente sustituido es opcionalmente sustituido por uno o más sustituyentes,
ARP990102812A 1998-06-12 1999-06-11 Compuestos de beta-carbolina, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento y compuesto intermediario AR019153A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9729798A 1998-06-12 1998-06-12
US8918098P 1998-06-12 1998-06-12

Publications (1)

Publication Number Publication Date
AR019153A1 true AR019153A1 (es) 2001-12-26

Family

ID=26780327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102812A AR019153A1 (es) 1998-06-12 1999-06-11 Compuestos de beta-carbolina, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento y compuesto intermediario

Country Status (22)

Country Link
US (1) US6586445B1 (es)
EP (1) EP1086101B1 (es)
JP (1) JP2002517500A (es)
KR (1) KR20010071461A (es)
CN (1) CN1169808C (es)
AR (1) AR019153A1 (es)
AT (1) ATE229954T1 (es)
AU (1) AU761020B2 (es)
CA (1) CA2335339A1 (es)
CZ (1) CZ20004580A3 (es)
DE (1) DE69904595T2 (es)
DK (1) DK1086101T3 (es)
ES (1) ES2188184T3 (es)
HK (1) HK1032049A1 (es)
HU (1) HUP0302962A2 (es)
IL (1) IL140197A0 (es)
NO (1) NO319532B1 (es)
NZ (1) NZ508765A (es)
PL (1) PL345589A1 (es)
RU (1) RU2233841C2 (es)
TW (1) TWI236477B (es)
WO (1) WO1999064420A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6696418B1 (en) 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
FR2812546B1 (fr) * 2000-08-01 2008-11-21 Sod Conseils Rech Applic Derives d'heterocycles a 5 chainons, leur preparation et leur application a titre de medicaments
TWI283577B (en) * 1999-10-11 2007-07-11 Sod Conseils Rech Applic Pharmaceutical composition of imidazole derivatives acting as modulators of sodium channels and the use thereof
US6495589B2 (en) 2000-04-28 2002-12-17 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
FR2818978B1 (fr) * 2000-12-28 2003-02-28 Sod Conseils Rech Applic Modulateurs de canaux sodiques derives de 2-piperidylimidazoles
GB0108337D0 (en) 2001-04-03 2001-05-23 Novartis Ag Organic compounds
TWI248438B (en) * 2001-04-10 2006-02-01 Sod Conseils Rech Applic Derivatives of heterocycles with 5 members, their preparation and their use as medicaments
CZ20033123A3 (cs) * 2001-06-25 2004-11-10 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farmaceutické prostředky, které inhibují proliferaci adenomů hypofýzy
DE10136842A1 (de) * 2001-07-23 2003-02-13 Schering Ag GABA¶A¶-Rezeptor-Modulatoren mit NMDA-antagonistischer Aktivität
US7595311B2 (en) 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
PA8586801A1 (es) 2002-10-31 2005-02-04 Pfizer Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
DE10252667A1 (de) 2002-11-11 2004-05-27 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
BRPI0407052A (pt) 2003-01-27 2006-01-17 Pfizer Inibidores da hiv-integrase, composições farmacêuticas, e métodos para sua utilização
DE602004026289D1 (de) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminylcyclase-hemmer
CN101837127A (zh) 2003-05-05 2010-09-22 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
WO2004113300A1 (ja) 2003-06-23 2004-12-29 Ono Pharmaceutical Co., Ltd. 新規三環性複素環化合物
WO2005039548A2 (en) 2003-10-15 2005-05-06 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
DE10360793A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
AU2005210004B2 (en) 2004-02-05 2010-10-28 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ATE541835T1 (de) * 2004-02-05 2012-02-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
JP2007534738A (ja) 2004-04-26 2007-11-29 ファイザー・インク Ｈｉｖインテグラーゼ酵素の阻害剤
WO2005103003A2 (en) 2004-04-26 2005-11-03 Pfizer Inc. Pyrrolopyridine derivatives and their use as hiv-integrase inhibitors
DE102004039382A1 (de) 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP1829874B1 (en) 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2006089053A2 (en) 2005-02-17 2006-08-24 Wyeth Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
MY144968A (en) * 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
JP5035865B2 (ja) * 2005-09-26 2012-09-26 国立大学法人高知大学 Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ菌株の増殖・運動抑制方法
WO2007062175A2 (en) * 2005-11-21 2007-05-31 Amgen Inc. Spiro-substituted tricyclic heterocycles cxcr3 antagonists
US7879859B2 (en) * 2005-11-21 2011-02-01 Merck Sharp & Dohme Corp. Diagnosis and treatment of type 2 diabetes and other disorders
CN101346375B (zh) * 2005-11-23 2013-04-10 阿罗斯药物有限责任公司 调节门离子通道用组合物和方法
US20080004306A1 (en) * 2006-04-10 2008-01-03 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
DE102006046745A1 (de) * 2006-09-29 2008-04-03 Grünenthal GmbH Gemischte ORL1/µ-Agonisten zur Behandlung von Schmerz
CA2693214A1 (en) * 2007-07-19 2009-01-22 Merck Sharp & Dohme Corp. Beta carboline derivatives as antidiabetic compounds
SG10201703086VA (en) * 2008-10-17 2017-05-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
WO2010051177A1 (en) * 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Triazole beta carboline derivatives as antidiabetic compounds
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
CN102844029A (zh) * 2009-12-28 2012-12-26 奥迪欧医药设备有限公司 用于治疗听力损伤和眩晕的β-咔啉
CN102695414A (zh) 2010-01-15 2012-09-26 默沙东公司 作为抗糖尿病化合物的噁二唑β-咔啉衍生物
KR101256588B1 (ko) * 2010-02-17 2013-04-19 부산대학교 산학협력단 베타-카르볼린 알칼로이드를 함유하는 멜라닌 생성 촉진용 조성물
KR101784284B1 (ko) * 2011-03-28 2017-10-11 에스제이티 몰레큘라 리서치, 에스.엘. 대사증후군 치료 화합물
CN105837569B (zh) * 2016-04-29 2017-12-26 华南农业大学 一种骆驼蓬碱噁唑啉类化合物及其制备方法和应用
CN107118212B (zh) * 2017-05-26 2019-12-03 广西师范大学 1-吡啶-6-甲氧基-9-(3-碘苄)-β-咔啉、合成和应用
CN107163041B (zh) * 2017-05-26 2019-06-21 广西师范大学 一种β-咔啉化合物及其合成方法和应用
CN106995440B (zh) * 2017-05-26 2019-09-03 广西师范大学 1-吡啶-6-甲氧基-9-(2，3，4，5-四氟苄基)β-咔啉化合物及其合成方法和应用
CN107141285B (zh) * 2017-05-26 2019-12-03 广西师范大学 1-吡啶-6-甲氧基-9-甲基苄-β-咔啉及其合成和应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378803A (en) * 1987-12-11 1995-01-03 Sterling Winthrop Inc. Azole-fused peptides and processes for preparation thereof

Also Published As

Publication number Publication date
ES2188184T3 (es) 2003-06-16
RU2233841C2 (ru) 2004-08-10
IL140197A0 (en) 2002-02-10
DE69904595D1 (de) 2003-01-30
CN1169808C (zh) 2004-10-06
DK1086101T3 (da) 2003-03-31
CA2335339A1 (en) 1999-12-16
ATE229954T1 (de) 2003-01-15
NO20006268D0 (no) 2000-12-11
DE69904595T2 (de) 2003-11-27
US6586445B1 (en) 2003-07-01
EP1086101B1 (en) 2002-12-18
WO1999064420A1 (en) 1999-12-16
PL345589A1 (en) 2001-12-17
JP2002517500A (ja) 2002-06-18
HK1032049A1 (en) 2001-07-06
NZ508765A (en) 2003-10-31
AU4553699A (en) 1999-12-30
AU761020B2 (en) 2003-05-29
EP1086101A1 (en) 2001-03-28
NO319532B1 (no) 2005-08-29
NO20006268L (no) 2001-01-29
CZ20004580A3 (cs) 2001-12-12
HUP0302962A2 (hu) 2003-12-29
CN1308632A (zh) 2001-08-15
TWI236477B (en) 2005-07-21
KR20010071461A (ko) 2001-07-28

Similar Documents

Publication Publication Date Title
AR019153A1 (es) Compuestos de beta-carbolina, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento y compuesto intermediario
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
DK0971878T3 (da) Aminforbindelser, fremstillingen og anvendelsen deraf som inhibitorer af amyloid-beta-produktion
UY25811A1 (es) Derivados de pirrolidina que son antagonistas del receptor ccr-3
FI970317A0 (fi) Antiproliferatiivisina aineina ja Garft-inhibiittoreina käyttökelpoisia yhdisteitä
UY25142A1 (es) Antagonistas del receptor ccr-3
DE3850742D1 (de) Neue 4-Oxobenzotriazine und 4-Oxochinazoline.
CO4480737A1 (es) Compuestos parasiticidas
ATE270271T1 (de) Sulfonamidhydroxamate
AU3927197A (en) New flavone compounds, process for preparing them and pharmaceutical compositions containing them
AR009363A1 (es) Compuestos 3-mercaptoacetilamino-1,5-sustituido--oxo-azepan utiles como inhibidores de metaloproteinasas de la matriz, composicion farmaceutica y usos para la fabricacion de medicamentos para el tratamiento de enfermedades que responden a la inhibicion de metaloproteinasas de la matriz
TW356468B (en) Benzothiazolone compounds useful as beta2-adrenoreceptor and dopamine DA2 receptor agonists process for preparing same and pharmaceutical compositions containing same
HUP0203275A2 (hu) 1-(Gyűrűs amino)-alkilciklohexán-származékok, ezeket tartalmazó görcsoldó hatású gyógyszerkészítmények, valamint ezek alkalmazása
AR054414A1 (es) Compuestos espiro-hidantoina sustituidos con piridilo. composiciones farmaceuticas.
DK0541263T3 (da) 5-Piperazinylalkyl-1,5-benzothiazepinoner, der er nyttige som calciumantagonister
ATE196464T1 (de) Benzol-derivate, verwendbar für ischämische erkrankungen
AR034692A1 (es) Inhibidores de la integrina alfavbeta3, un procedimiento para su preparacion, los medicamentos a base de estos compuestos, las composiciones farmaceuticas que los contienen y el uso de los mismos para preparar un medicamento destinado a combatir enfermedades que se basan en la expresion y funcion pa
ES545313A0 (es) Procedimiento para la preparacion de un nuevo derivado de lafenil-3 propeno-2 amina
AR002715A1 (es) Derivados de piperazina y piperazinona heterociclos substituidos particularmente utiles como antagonistas de los receptores de taquikinina,composicion farmaceutica que incluye uno de dichos derivados, uso de dichos compuestos en la preparacion de las composiciones y procedimiento para la preparacion de los derivados
FI950818A (fi) Uudet substituoidut sulfoniamidit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
ES2174582T3 (es) Nuevos derivados de 1,2-ditiolano, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
NO973442D0 (no) Nye bismidforbindelser, fremgangsmåte ved fremstilling derav og farmasöytiske sammensetninger inneholdende slike
ECSP982791A (es) Compuestos organicos
AT389113B (de) Neue benzothiazinon-derivate, verfahren zu ihrer herstellung, sie enthaltende arzneimittel und deren verwendung
DK0570443T3 (da) Aminoalkoholer, der er egnede som midler til optisk opløsning

Legal Events

Date Code Title Description
FA Abandonment or withdrawal